We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01734447
First Posted: November 27, 2012
Last Update Posted: February 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novo Nordisk A/S
  Purpose
This trial is conducted in Europe. The aim of this trial is to assess the safety of long-term growth hormone treatment in growth-retarded children with intrauterine growth retardation (IUGR) enrolled in trial GHRETARD/F/1/F.

Condition Intervention Phase
Foetal Growth Problem Small for Gestational Age Drug: somatropin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Discontinued Administration (6 Months a Year) of Growth Hormone to Children With Very Short Stature and Having Suffered From Intrauterine Growth Retardation: Safety and Effect on Growth of Long-term Therapy

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Glucose tolerance as assessed by hyperglycaemia induced by oral ingestion

Secondary Outcome Measures:
  • Bone Age determined according to Greulich and Pyle method and measured on the left hand X-ray
  • Pubertal development, assessed according to Tanner method
  • Height velocity
  • Final height
  • Number of Adverse Events

Enrollment: 57
Actual Study Start Date: April 30, 2000
Study Completion Date: April 30, 2003
Primary Completion Date: April 30, 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1.2, continuous treatment Drug: somatropin
1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months
Experimental: 1.2, non-continuous treatment Drug: somatropin
1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
Experimental: 2.4, non-continuous treatment Drug: somatropin
2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients born with IUGR enrolled in trial GHRETARD/F/1/F
  • Bone age below 14 years in boys and 12 years in girls

Exclusion Criteria:

  • Bone age above 14 years in boys and 12 years in girls
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01734447


Locations
France
Novo Nordisk Investigational Site
Paris, France
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01734447     History of Changes
Other Study ID Numbers: GHRETARD/F/2/F
First Submitted: November 22, 2012
First Posted: November 27, 2012
Last Update Posted: February 28, 2017
Last Verified: February 2017

Additional relevant MeSH terms:
Fetal Growth Retardation
Fetal Diseases
Pregnancy Complications
Growth Disorders
Pathologic Processes